Kihealth Labs was founded on a simple belief: healthcare should identify disease earlier, when there is still time to intervene, still time to change the outcome, and still time to protect what matters most.
For decades, healthcare has been built around diagnosing disease after symptoms appear. Kihealth was founded on a different belief: that the future of medicine lies in identifying biological changes earlier, enabling intervention before irreversible damage occurs.
Translating breakthrough molecular science into clinically actionable diagnostics.
Home to our high-complexity molecular laboratory and corporate offices.
The foundational technology behind Kihealth originated at Yale University, where pioneering work by Dr. Kevin Herold demonstrated the potential to detect beta-cell injury using circulating biomarkers. This scientific breakthrough opened a new lens on chronic disease, one that revealed molecular signals long before symptoms, long before clinical diagnosis, and long before irreversible damage had already taken place.
That discovery created a rare opportunity: to rethink how chronic diseases, particularly Type 1 and Type 2 diabetes, could be identified much earlier than traditional approaches allow. For decades, medicine has waited for disease to declare itself. This science offered the possibility of listening for it, quietly, at a molecular level, years earlier.
Kihealth Labs was founded in 2023 with a singular mission: to translate this groundbreaking science into clinically accessible diagnostics capable of changing how diseases are detected, monitored, and ultimately prevented. Not confined to a research paper. Not reserved for a small handful of academic centers. But delivered, reliably, affordably, and at scale, to the clinicians and patients who need it.
Today, Kihealth continues advancing and commercializing this technology through its high-complexity molecular laboratory in St. Augustine, Florida, working alongside leading physicians, researchers, academic institutions, healthcare systems, and industry partners to bring these innovations into real-world clinical practice.
Great science only matters when it reaches the people it was meant to help.
Two ideas guide every decision at Kihealth: a clear sense of purpose today, and a long-term vision for a healthcare system built around prevention.
Our mission is to empower clinicians with earlier, more actionable molecular insights that enable earlier disease detection, improve therapeutic decision-making, support treatment monitoring, and ultimately help patients live healthier lives.
We are committed to transforming healthcare from a reactive model into one centered on prevention, precision, and earlier intervention.
We envision a future where molecular diagnostics become a routine part of clinical care, equipping physicians with powerful new tools to identify disease earlier, personalize treatment, monitor therapeutic response, and improve patient outcomes across chronic diseases.
Our long-term vision is to help build a healthcare system that focuses on preventing disease progression rather than simply treating its consequences.
Identify molecular signals of disease years before symptoms or clinical diagnosis.
Give clinicians objective, actionable data to guide diagnosis and treatment planning.
Track how patients are responding to therapy with sensitive molecular readouts.
Support pharmaceutical partners with biomarkers that sharpen trial endpoints.
Match the right intervention to the right patient at the right point in the disease.
Turn earlier insight into earlier action — and better long-term health for patients.
Every breakthrough begins in a lab, and matters only when it reaches the clinic.
Each chapter builds on the last — from a single laboratory discovery to a molecular diagnostics platform reaching clinicians and patients.
Discovery of circulating beta-cell biomarkers under Dr. Kevin Herold's lab establishes a new way to detect organ-specific injury.
Company established with a singular mission: translate breakthrough science into clinically accessible diagnostics. A CLIA- and COLA-certified high-complexity molecular laboratory was established in St. Augustine, Florida to support assay development, validation, and clinical reporting.
Our assays have been validated as a lab-derived test, with expansion through leading academic and medical centers and multi-center research collaborations for continued clinical validation.
Proprietary artificial intelligence and machine-learning layer that integrates multi-omic signal, longitudinal clinical data, and predictive modeling to power Intercept IQ™.
Development of a scalable molecular diagnostics platform for disease interception across multiple indications.
The first commercial-ready diagnostic built on Intercept IQ™ — clinically validated to detect beta-cell injury earlier in Type 1 diabetes.
A precision diagnostic for Type 2 diabetes, prediabetes, and metabolic dysfunction — designed to guide prevention and therapeutic monitoring.
Preparing next-generation diagnostics for physicians, patients, and health systems nationwide.
Advancing disease interception across multiple therapeutic areas and international markets.
Kihealth exists at the intersection of science, medicine, and the people whose lives depend on both.
Kihealth exists at the intersection of patients, clinicians, researchers, and institutions — each with a unique stake in what disease interception can make possible.
Behind every diagnostic is a family hoping for earlier answers, better outcomes, and more time together.
We believe the future of healthcare begins with earlier answers. By equipping clinicians with better tools, supporting therapeutic innovation, and advancing disease interception, we are working toward a future where fewer people experience the devastating consequences of preventable chronic disease.
